

EIP



AstraZeneca patent revoked for obviousness

In a decision on 22 March in *Teva and ors v AstraZeneca* concerning a patent on a sustained release formulation of an anti-psychotic drug, Mr Justice Arnold revoked the patent due to obviousness.

In his [IPKat](#) blog, Darren Smyth draws comparisons between this decision and that of *Actavis v Novartis*, which involved a patent concerning a sustained release formulation of fluvastatin that was held to be obvious.